These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 17075808

  • 41. Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy.
    Kanno A, Hotta O, Yusa N, Taguma Y.
    Ren Fail; 2007; 29(1):41-7. PubMed ID: 17365909
    [Abstract] [Full Text] [Related]

  • 42. [Intravenous cyclophosphamide in lupus nephritis: twenty years reducing dose].
    Frutos MA, Martín Gómez A, de Ramón E, Camps MT, Valera A, García I, Fernández Nebro A.
    Nefrologia; 2007; 27(1):12-22. PubMed ID: 17402875
    [Abstract] [Full Text] [Related]

  • 43. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up.
    Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P, Ponticelli C.
    Nephrol Dial Transplant; 2006 Jun; 21(6):1541-8. PubMed ID: 16455674
    [Abstract] [Full Text] [Related]

  • 44. [The efficacy of cyclophosphamide bolus therapy in a girl with SLE with a nephritic onset].
    Ballati G, Tucciarone L, Diamanti A, Frangella E, Chiaramida N.
    Minerva Pediatr; 1991 Sep; 43(9):573-6. PubMed ID: 1758394
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.
    Jónsdóttir T, Zickert A, Sundelin B, Henriksson EW, van Vollenhoven RF, Gunnarsson I.
    Rheumatology (Oxford); 2013 May; 52(5):847-55. PubMed ID: 23287364
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis.
    Couzi L, Merville P, Deminière C, Moreau JF, Combe C, Pellegrin JL, Viallard JF, Blanco P.
    Arthritis Rheum; 2007 Jul; 56(7):2362-70. PubMed ID: 17599764
    [Abstract] [Full Text] [Related]

  • 54. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.
    Arthritis Rheum; 2009 Apr 15; 61(4):482-7. PubMed ID: 19333973
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival.
    Vagenas K, Spyropoulos C, Gavala V, Tsamandas AC.
    J Surg Res; 2007 May 15; 139(2):182-8. PubMed ID: 17270215
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Lupus nephritis.
    Sauter M, Anders HJ.
    Minerva Med; 2007 Dec 15; 98(6):749-58. PubMed ID: 18299686
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.